Description
ProAgio is an investigational medication currently being studied in clinical trials for advanced or metastatic colorectal cancer (CRC). It is being tested in combination with standard chemotherapy regimens like FOLFIRI (5-fluorouracil, irinotecan) and bevacizumab. The goal of these early-phase trials (Phase 1) is primarily to determine the safest dose of ProAgio when given with these other drugs and to see if the combination shows any signs of effectiveness in shrinking tumors or slowing disease progression. These trials are open-label, meaning both the researchers and the participants know which treatment is being given. The trials are enrolling patients who have not received prior treatment for their advanced CRC.
Mechanism of Action
ProAgio is being investigated as a potential treatment for CRC. The specific way it works (its mechanism of action) is still being studied in clinical trials. Researchers are evaluating how it interacts with cancer cells and the body's immune system, particularly when combined with standard chemotherapy and bevacizumab.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.